ArticleDiabetes2015
A mutant allele encoding DNA binding-deficient FoxO1 differentially regulates hepatic glucose and lipid metabolism.
Article in Diabetes, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Modification of adipose mass by targeting distal enhancers of Ptrf.BMC biology · 2025Article
- FOXO transcription factors as therapeutic targets in human diseases.Trends in pharmacological sciences · 2022Review
- Hepatic FoxOs link insulin signaling with plasma lipoprotein metabolism through an apolipoprotein M/sphingosine-1-phosphate pathway.The Journal of clinical investigation · 2022Article
- Hepatic transcriptional profile reveals the role of diet and genetic backgrounds on metabolic traits in female progenitor strains of the Collaborative Cross.Physiological genomics · 2021Article
- Mechanism of Lipid Accumulation through PAR2 Signaling in Diabetic Male Mice.Endocrinology and metabolism (Seoul, Korea) · 2021Article
- Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway.BMC immunology · 2020Article
- Review
- Forkhead Domains of FOXO Transcription Factors Differ in both Overall Conformation and Dynamics.Cells · 2019Article
- A fluorescent reporter assay of differential gene expression response to insulin in hepatocytes.American journal of physiology. Cell physiology · 2019Article
- Article
- Regulation of hepatic glucose production and AMPK by AICAR but not by metformin depends on drug uptake through the equilibrative nucleoside transporter 1 (ENT1).Diabetes, obesity & metabolism · 2018Article
- microRNA-205-5p is a modulator of insulin sensitivity that inhibits FOXO function.Molecular metabolism · 2018Article
- Mechanisms of Insulin Action and Insulin Resistance.Physiological reviews · 2018Review
- FoxO transcription factors are required for hepatic HDL cholesterol clearance.The Journal of clinical investigation · 2018Article
- Enhancement of Adiponectin Ameliorates Nonalcoholic Fatty Liver Disease via Inhibition of FoxO1 in Type I Diabetic Rats.Journal of diabetes research · 2018Article
- Selective Inhibition of FOXO1 Activator/Repressor Balance Modulates Hepatic Glucose Handling.Cell · 2017Article
- FOXO transcription factors in non-alcoholic fatty liver disease.Liver research (Beijing, China) · 2017Article
- FOXO transcription factors protect against the diet-induced fatty liver disease.Scientific reports · 2017Article
- Article
- LncRNA SRA promotes hepatic steatosis through repressing the expression of adipose triglyceride lipase (ATGL).Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Insulin signaling in the liver blunts glucose production and stimulates triglyceride biosynthesis. FoxO1 is required for cAMP induction of hepatic glucose production and is permissive for the effect of insulin to suppress this process. Moreover, FoxO1 ablation increases lipogenesis. In this study, we investigated the pleiotropic actions of FoxO1 on glucose and lipid metabolism. To this end, we reconstituted FoxO1 function in mice with a liver-specific deletion of Foxo1 using targeted knock-in of an allele encoding a DNA binding-deficient FoxO1 mutant (L-DBD). Chow-reared L-DBD mice showed defects in hepatic glucose production but normal liver triglyceride content despite increased rates of de novo lipogenesis and impaired fatty acid oxidation in isolated hepatocytes. Gene expression studies indicated that FoxO1 regulates the expression of glucokinase via a cell-nonautonomous coregulatory mechanism, while its regulation of glucose-6-phosphatase proceeds via a cell-autonomous action as a direct transcriptional activator. These conclusions support a differential regulation of hepatic glucose and lipid metabolism by FoxO1 based on the mechanism by which it alters the expression of key target genes involved in each process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.